Vir Biotechnology (VIR) Receivables - Accured (2020 - 2024)
Vir Biotechnology (VIR) posted Receivables - Accured of $5.7 million for Q1 2024, up 42.5% sequentially from $4.0 million in Q4 2023, and up 171.43% YoY from $2.1 million in Q2 2023.
Vir Biotechnology (VIR) Receivables - Accured (2020 - 2024) Analysis & Trends
Vir Biotechnology has reported Receivables - Accured for 5 years, with the latest figure at $5.7 million in Q1 2024.
- Quarterly Receivables - Accured rose 171.43% year-over-year to $5.7 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $5.7 million (up 171.43% YoY) and the FY2023 annual result came in at $4.0 million, up 60.0% from the prior year.
- Receivables - Accured advanced to $5.7 million in Q1 2024 per VIR's latest filing, from $4.0 million in the prior quarter.
- Over five years, Receivables - Accured peaked at $5.7 million in Q1 2024 and troughed at $600000.0 in Q2 2021.
- A 5-year average of $2.1 million and a median of $1.8 million in 2022 frame the typical range for Receivables - Accured.
- The widest YoY moves for Receivables - Accured: up 250.0% in 2022, down 0.0% in 2022.
- Over 5 years, Receivables - Accured stood at $800000.0 in 2020, then jumped by 37.5% to $1.1 million in 2021, then surged by 127.27% to $2.5 million in 2022, then soared by 60.0% to $4.0 million in 2023, then soared by 42.5% to $5.7 million in 2024.
- According to Business Quant data, Receivables - Accured over the past three periods registered $5.7 million, $4.0 million, and $2.9 million for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 5.70 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Dec 31, 2023 | 4.00 Mn |
| Dec 31, 2023 | 4.00 Mn |
| Sep 30, 2023 | 2.90 Mn |
| Sep 30, 2023 | 2.90 Mn |
| Jun 30, 2023 | 1.90 Mn |
| Jun 30, 2023 | 1.90 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 1.80 Mn |
| Jun 30, 2022 | 1.80 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Dec 31, 2021 | 1.10 Mn |